The crude incidence rate of melanoma-related death 20 years after diagnosis was 6% for those with tumors thinner than 0.8 mm.
Health Professionals
Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
Tumor Upstaging in Invasive Melanoma Linked to Worse Survival Outcomes
Shortfalls in clinical management may explain why tumor upstaging in invasive melanoma is associated with worse survival outcomes, according to study findings published in the Journal of the American Academy of Dermatology.
mmune Checkpoint Inhibitors for Advanced Melanoma: 10-Year Outcomes Turn Heads
The final, 10-year results of the international randomised clinical trial known as CheckMate 067 report that the median overall survival with advanced melanoma is nearly 72 months with the combination of nivolumab + ipilimumab, nearly 37 months with nivolumab monotherapy, and only 20 months with ipilimumab monotherapy. Both agents are immune checkpoint inhibitors, but their immune targets differ.